CLEVELAND – July 1, 2015
Sujana Biotech is a company developing novel therapeutics for a range of inflammatory and vascular disorders. The company is being launched by BioMotiv in partnership with scientific founder and Harrington Scholar Daniel Simon, MD (University Hospitals Harrington Heart & Vascular Institute) and his colleagues Edward Plow, PhD (Cleveland Clinic) and Yunmei Wang, PhD (Case Western Reserve University). The founders have identified a unique binding site on the leukocyte integrin Mac-1 that is responsible for the pathologic recruitment and activation of leukocytes at sites of vascular injury. The technology is licensed from Case Western Reserve University.